Baird raised the firm’s price target on Labcorp to $282 from $278 and keeps an Outperform rating on the shares. In the firm’s Q2 Contract Research Organization, or CRO, quarterly review and outlook note, the analyst says “fundamentals weakened, tone shifted, confusion reigned supreme since Q2.” However, Baird adds that “September changed the narrative, keeping us on board into earnings.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LH:
- Labcorp Completes Acquisition of Select Assets of BioReference Health’s Diagnostics Business from OPKO Health
- Labcorp Executives to Present at Global Healthcare Conference
- Bio-Rad Labcorp announces Jon DiVincenzo as COO
- Labcorp price target raised to $260 from $240 at BofA
- Labcorp completes acquisition of select assets of Invitae